Upon engagement with gp100-expressing tumor cells, tebentafusp facilitates the recruitment of both CD4+ and CD8+ T lymphocytes, resulting in T cell activation, pro-inflammatory cytokine production, and tumor cell lysis. Here, CD8A is linked to neoplasm.